Financing channel feed

Kyver­na seeks $182M IPO as biotech runs mul­ti­ple au­toim­mune CAR-T tri­als

Last year
Cell/Gene Tx

Vax­cyte prices $750M of­fer­ing, one of biotech’s largest, as it goes up against Big Phar­ma's pneu­mo­coc­cal vac­cines

Last year

Dana­her out­does low fourth-quar­ter rev­enue ex­pec­ta­tions, fore­casts slow 2024

Last year
Diagnostics

Chica­go-area au­toim­mune biotech gets phar­ma back­ing in $105M round for two PhII tri­als

Last year
Startups

Mid-stage CNS biotech Al­to Neu­ro­science plots $89M IPO

Last year
Startups

Fractyl has the GUTS: Obe­si­ty and di­a­betes biotech charts $99M IPO

Last year
Cell/Gene Tx

Ex­clu­sive: UK biotech rais­es $33.1M to test CF drug that could work on top of stan­dard of care

Last year

In­no­va­tion En­deav­ors’ Joel Dud­ley on grow­ing in­ter­est in life sci­ences with new fund — and why he hates ‘tech­bio’

Last year
People

UK's 're­silien­t' life sci­ences sec­tor hopes for up­turn af­ter de­creas­es in fi­nanc­ing, ven­ture cap­i­tal in 2023 — re­port

Last year

Ar­riVent prices $175M IPO in back-to-back on­col­o­gy biotech list­ings

Last year

Is CG On­col­o­gy’s IPO a bench­mark for a bet­ter year in pub­lic of­fer­ings? 

Last year

Biotech's 2024 IPO sea­son kicks off with heavy de­mand for CG On­col­o­gy in $380M list­ing

Last year

LB Phar­ma­ceu­ti­cals clos­es $75M Se­ries C as it be­gins PhII schiz­o­phre­nia tri­al

Last year
Startups

Ex­clu­sive: Reid Hu­ber re­unites with for­mer In­cyte col­league Wen­qing Yao, backs Syn­no­va­tion with $102M for three tri­als

Last year
Startups

Gene edit­ing de­liv­ery biotech GenEd­it part­ners with Genen­tech, rais­es an­oth­er $24M

Last year
Startups
Pharma

On­col­o­gy biotech Ac­cent rais­es $75M to en­ter the clin­ic

Last year
Startups

Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Last year
Startups
China

Ex­clu­sive: Two biotechs merge to form Cal­lu­na, with €75M in hand to fo­cus on im­munother­a­py an­ti­bod­ies

Last year
Deals

New­ly hope­ful, bio­phar­ma still faces an un­cer­tain 2024

Last year
Pharma

Re­turn of the SPAC? Bi­hua Chen and Cor­morant go for round two af­ter Moon­Lake suc­cess

Last year

Bridge­Bio rais­es up to $1.2B, a month af­ter sub­mit­ting car­dio drug to FDA

Last year

CG On­col­o­gy aims for $181M list­ing in first biotech IPO of 2024

Last year

In­vest­ment firm Mi­rae launch­es its US biotech VC fund with $50M

Last year

Graphite Bio co-founder de­buts Treg cell ther­a­py start­up with $75M, aims to ‘trick’ im­mune sys­tem in­to re­set­ting

Last year
Startups
Cell/Gene Tx
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times